ヘルプ
ヘルプ

検索結果 22 件

A propensity analysis of cigarette smoking and mortality with consideration of the effects of alcohol∗∗Note: This study uses data supplied by the National Heart, Lung, and Blood Institute, National Institutes of Health, United States Department of Health and Human Services, Bethesda, Maryland. The views expressed in this study are those of the authors and do not necessarily reflect the views of the National Heart, Lung, and Blood Institute.

A propensity analysis of cigarette smoking and mortality with consideration of the effects of alcohol∗∗Note: This study uses data supplied by the National Heart, Lung, and Blood Institute, National Institutes of Health, United States Department of Health and Human Services, Bethesda, Maryland. The views expressed in this study are those of the authors and do not necessarily reflect the views of the National Heart, Lung, and Blood Institute.
デジタル記事
2001-03The American Journal of Cardiology87 6p.706-711
全国の図書館
  • 参照Smoking and Risk of All-cause Mortality: The Jichi Medical School (JMS) Co...

Usefulness of Red Cell Distribution Width as a Prognostic Marker in Pulmonary Hypertension††Conflicts of interest: Dr. Gomberg-Maitland has received research grant support from Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; CoTherix, Inc., South San Francisco, California; Encysive Pharmaceuticals Inc., Houston, Texas; Gilead Sciences Inc., Foster City, California; Eli Lilly/ICOS, Indianapolis, Indiana; Pfizer Inc., New York, New York; and United Therapeutics, Silver Spring, Maryland. Dr. Gomberg-Maitland has served as a consultant and/or on advisory boards for Encysive Pharmaceuticals Inc., Gilead Sciences Inc., Pfizer Inc., and United Therapeutics. Dr. Shah has received research grant support from Actelion Pharmaceuticals Ltd. (Entelligence Young Investigator Award) and is also the recipient of a Scientist Development Grant from the American Heart Association, Dallas, Texas.

Usefulness of Red Cell Distribution Width as a Prognostic Marker in Pulmonary Hypertension††Conflicts of interest: Dr. Gomberg-Maitland has received research grant support from Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; CoTherix, Inc., South San Francisco, California; Encysive Pharmaceuticals Inc., Houston, Texas; Gilead Sciences Inc., Foster City, California; Eli Lilly/ICOS, Indianapolis, Indiana; Pfizer Inc., New York, New York; and United Therapeutics, Silver Spring, Maryland. Dr. Gomberg-Maitland has served as a consultant and/or on advisory boards for Encysive Pharmaceuticals Inc., Gilead Sciences Inc., Pfizer Inc., and United Therapeutics. Dr. Shah has received research grant support from Actelion Pharmaceuticals Ltd. (Entelligence Young Investigator Award) and is also the recipient of a Scientist Development Grant from the American Heart Association, Dallas, Texas.
デジタル記事
2009-09The American Journal of Cardiology104 6p.868-872
全国の図書館
  • 参照...dictive Factor of Anthracycline-......ognostic Value of Change in Red ...... Decompensated Heart Failure Patients Usefulness of Red Blood Cell......ution Width in the Assessment of Hemodynamics After Tetralogy of Fallot Repair
  • 著者標目Chetan V. Hampole Amit K. Mehrotra Thenappan Thenappan Mardi Gomberg-Maitland ...

Warfarin Anticoagulation and Survival: A Cohort Analysis From the Studies of Left Ventricular Dysfunction 11This study was supported by Grant MO1-RR00054 from the General Clinical Research Center, funded by the Division of Research Resources, National Institutes of Health, Bethesda, Maryland. The Studies of Left Ventricular Dysfunction (SOLVD) were funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, with a contribution from Merck, Sharpe and Dohme Pharmaceutical Company, West Point, Pennsylvania.

Warfarin Anticoagulation and Survival: A Cohort Analysis From the Studies of Left Ventricular Dysfunction 11This study was supported by Grant MO1-RR00054 from the General Clinical Research Center, funded by the Division of Research Resources, National Institutes of Health, Bethesda, Maryland. The Studies of Left Ventricular Dysfunction (SOLVD) were funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, with a contribution from Merck, Sharpe and Dohme Pharmaceutical Company, West Point, Pennsylvania.
デジタル記事
1998-03Journal of the American College of Cardiology31 4p.749-753
全国の図書館

Assessment of Platelet Activation by Coronary Sinus Blood Sampling During Balloon Angioplasty and Directional Coronary Atherectomy11This study was supported by the National Heart, Lung, and Blood Institute Specialized Center of Research Grant in Thrombosis (HL26309-15), Bethesda, Maryland.

Assessment of Platelet Activation by Coronary Sinus Blood Sampling During Balloon Angioplasty and Directional Coronary Atherectomy11This study was supported by the National Heart, Lung, and Blood Institute Specialized Center of Research Grant in Thrombosis (HL26309-15), Bethesda, Maryland.
デジタル記事
1997-10The American Journal of Cardiology80 7p.871-877
全国の図書館
  • 参照...onal Coronary Atherectomy Compare......onal Coronary Atherectomy Alone and Stenting Alo...

Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery11Supported, in part, by grant NCC9-60 from the National Aeronautics and Space Administration, Houston, Texas, Grant #9951522V from the America Heart Association Ohio Local Chapter, Columbus, Ohio and Grant #R01 HL56688-01A1 from the National Institutes of Health, Bethesda, Maryland.22Presented, in part, at the 49th Annual Scientific Sessions of American College of Cardiology, March 2000, Anaheim, California.

Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery11Supported, in part, by grant NCC9-60 from the National Aeronautics and Space Administration, Houston, Texas, Grant #9951522V from the America Heart Association Ohio Local Chapter, Columbus, Ohio and Grant #R01 HL56688-01A1 from the National Institutes of Health, Bethesda, Maryland.22Presented, in part, at the 49th Annual Scientific Sessions of American College of Cardiology, March 2000, Anaheim, California.
デジタル記事
2001-12Journal of the American College of Cardiology38 7p.1994-2000
全国の図書館
  • 参照...-up Results in the First 27 Patients-

C-Type Natriuretic Peptide-Mediated Coronary Vasodilation: Role of the Coronary Nitric Oxide and Particulate Guanylate Cyclase Systems11This study was supported in part by grants from the American Heart Association, Minnesota Affiliate, Minneapolis, Minnesota; the National Heart, Lung, and Blood Institute (Grant HL-033643), National Institutes of Health, Bethesda, Maryland; and the Mayo Foundation, Rochester, Minnesota.

C-Type Natriuretic Peptide-Mediated Coronary Vasodilation: Role of the Coronary Nitric Oxide and Particulate Guanylate Cyclase Systems11This study was supported in part by grants from the American Heart Association, Minnesota Affiliate, Minneapolis, Minnesota; the National Heart, Lung, and Blood Institute (Grant HL-033643), National Institutes of Health, Bethesda, Maryland; and the Mayo Foundation, Rochester, Minnesota.
デジタル記事
1996-10Journal of the American College of Cardiology28 4p.1031-1038
全国の図書館
  • 参照...on During Waon Therapy in Chronic Heart Failure　― Subanalysis of Waon-CHF Study ―

Effect of Elevated Leukocyte Count on In-Hospital Mortality Following Acute Myocardial Infarction**This project was supported by grant R01-HL-35434 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland.

Effect of Elevated Leukocyte Count on In-Hospital Mortality Following Acute Myocardial Infarction**This project was supported by grant R01-HL-35434 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland.
デジタル記事
1996-10The American Journal of Cardiology78 8p.945-948
全国の図書館
  • 参照...n Significance of Neutrophil Cou......er Reperfusion Therapy in Patient......? Relationship of Admission Neutrophil Count to...

Cause of Death Analysis in the NHLBI PTCA Registry: Results and Considerations for Evaluating Long-Term Survival After Coronary Interventions fn1fn1This study was supported by Grant HL-33292 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Cause of Death Analysis in the NHLBI PTCA Registry: Results and Considerations for Evaluating Long-Term Survival After Coronary Interventions fn1fn1This study was supported by Grant HL-33292 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
デジタル記事
1997-10Journal of the American College of Cardiology30 4p.881-887
全国の図書館
  • 参照Analysis of the Clinical Chara......nt, and Causes of Death in Patients with ST-Seg...
  • 著者標目David R. Holmes Kevin E. Kip Sheryl F. Kelsey Katherine M. Detre Allan D. Rosen

Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5-6, 1991, Bethesda, Maryland.

Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5-6, 1991, Bethesda, Maryland.
デジタル記事
1992-06Circulation85 6p.2337-2344
全国の図書館
  • 参照Anchoring Transitions of Liquid Crystal...... Amplification of Phospholipid Oxidation Inhibi...

Antioxidants in the prevention of human atherosclerosis. Summary of the Proceedings of a National Heart, Lung, and Blood Institute workshop : September 5-6, 1991, Bethesda, Maryland

Antioxidants in the prevention of human atherosclerosis. Summary of the Proceedings of a National Heart, Lung, and Blood Institute workshop : September 5-6, 1991, Bethesda, Maryland
記事
1992Circulation85p.2338-2344
全国の図書館

The Electrocardiogram Predicts One-Year Outcome of Patients With Unstable Angina and Non–Q Wave Myocardial Infarction: Results of the TIMI III Registry ECG Ancillary Study fn1fn1The TIMI III Clinical Centers are supported by Grant R01-HL42311 and the Data Coordinating Center by Grant R01-HL42428 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. Additional support was supplied by Genentech, Inc., South San Francisco, California.

The Electrocardiogram Predicts One-Year Outcome of Patients With Unstable Angina and Non–Q Wave Myocardial Infarction: Results of the TIMI III Registry ECG Ancillary Study fn1fn1The TIMI III Clinical Centers are supported by Grant R01-HL42311 and the Data Coordinating Center by Grant R01-HL42428 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. Additional support was supplied by Genentech, Inc., South San Francisco, California.
デジタル記事
1997-07Journal of the American College of Cardiology30 1p.133-140
全国の図書館
  • 参照Paradoxical impact of decreased low-......at baseline on the long-term prog......ive Predictors of Left Main or 3......tter Predictor of Clinical Outco......rong Predictor of Adverse Outcom......l Implications of Electrocardiog......y Syndromes in the Interventional Era
  • 著者標目...iel J. Diver Catherine Kells Ted Feldman Marcus ...

Report of the second task force on blood pressure control in children-1987. National heart, lung, and blood institute, Bethesda, Maryland

Report of the second task force on blood pressure control in children-1987. National heart, lung, and blood institute, Bethesda, Maryland
記事
1987Pediatrics79p.1-25
全国の図書館

ACC/ACP/SCAI/SVMB/SVS clinical competence statement on vascular medicine and catheter-based peripheral vascular interventions11When citing this document, the American College of Cardiology, American College of Physicians, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and the Society for Vascular Surgery would appreciate the following citation format: Creager MA, Goldstone J, Hirshfeld JW, Kazmers A, Kent KC, Lorell BH, Olin JW, Pauly RR, Rosenfield K, Roubin GS, Sicard GA, and White CJ. ACC/ACP/SCAI/SVMB/SVS clinical competence statement on vascular medicine and catheter-based peripheral vascular interventions: a report of the American College of Cardiology/American Heart Association/American College of Physicians Task Force on Clinical Competence (ACC/ACP/SCAI/SVMB/SVS Writing Committee on Clinical Competence on Peripheral Vascular Disease). J Am Coll Cardiol 2004;44:941–57.33copies: this document is available on the world wide web sites of the american college of cardiology (www.acc.org), american college of physicians (www.acponline.org), society for cardiovascular angiography and interventions (www.scai.org), society for vascular medicine and biology (www.svmb.org), and the society for vascular surgeons (www.vascularweb.org). single copies of this document may be purchased for $10.00 by calling 1-800-253-4636 or by writing to the american college of cardiology, educational services, 9111 old georgetown road, bethesda, maryland 20814-1699. permissions: multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the american college of cardiology foundation. please direct requests to copyright_permissions@acc.org.

ACC/ACP/SCAI/SVMB/SVS clinical competence statement on vascular medicine and catheter-based peripheral vascular interventions11When citing this document, the American College of Cardiology, American College of Physicians, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and the Society for Vascular Surgery would appreciate the following citation format: Creager MA, Goldstone J, Hirshfeld JW, Kazmers A, Kent KC, Lorell BH, Olin JW, Pauly RR, Rosenfield K, Roubin GS, Sicard GA, and White CJ. ACC/ACP/SCAI/SVMB/SVS clinical competence statement on vascular medicine and catheter-based peripheral vascular interventions: a report of the American College of Cardiology/American Heart Association/American College of Physicians Task Force on Clinical Competence (ACC/ACP/SCAI/SVMB/SVS Writing Committee on Clinical Competence on Peripheral Vascular Disease). J Am Coll Cardiol 2004;44:941–57.33copies: this document is available on the world wide web sites of the american college of cardiology (www.acc.org), american college of physicians (www.acponline.org), society for cardiovascular angiography and interventions (www.scai.org), society for vascular medicine and biology (www.svmb.org), and the society for vascular surgeons (www.vascularweb.org). single copies of this document may be purchased for $10.00 by calling 1-800-253-4636 or by writing to the american college of cardiology, educational services, 9111 old georgetown road, bethesda, maryland 20814-1699. permissions: multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the american college of cardiology foundation. please direct requests to copyright_permissions@acc.org.
デジタル記事
2004-08Journal of the American College of Cardiology44 4p.941-957
全国の図書館
  • 参照... and Expansion of the TASC Lesion Cl...... Include Below-the-Knee Arteries:...... Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (...

Coronary heart disease in the elderly : Working Conference on the Recognition and Management of Coronary Heart Disease in the Elderly, held September 4-6, 1985, at the National Institutes of Health, in Bethesda, Maryland, U.S.A.

Coronary heart disease in the elderly : Working Conference on the Recognition and Management of Coronary Heart Disease in the Elderly, held September 4-6, 1985, at the National Institutes of Health, in Bethesda, Maryland, U.S.A.
紙図書
editors, Nanette K. Wenger, Curt D. Furberg, Elisabeth PittElsevierc1986
全国の図書館
  • 件名Old persons. Heart. Coronary diseases Coronary heart diseases -- Age factors Geria...
  • 件名（識別子）Old persons. Heart. Coronary diseases Coronary heart diseases -- Age factors Geria...
  • 著者標目Working Conference on the Recognition and Management of Coronary Heart Disease in the Elderly (1985 : Bethesda, Md.) Wenger, Nanette Kass...

Safety and Efficacy of Atorvastatin-Induced Very Low-Density Lipoprotein Cholesterol Levels in Patients With Coronary Heart Disease (a Post Hoc Analysis of the Treating to New Targets [TNT] Study)††Conflicts of interest: Dr. LaRosa has served as a consultant to Pfizer, Inc., New York, New York; Merck Whitehouse Station, New Jersey; Bristol-Myers Squibb, New York, New York; and AstraZeneca, Wilmington, Delaware; and has received lecture fees from Pfizer. Dr. Grundy has consulted with Abbott, Chicago, Illinois; GlaxoSmithKline, Durham, North Carolina, Pfizer, AstraZeneca, and Sanofi-Aventis, Bridgewater, New Jersey; received lecture fees from Merck Schering Plough, Kenilworth, New Jersey; Kos, Edison, New Jersey, Pfizer, GlaxoSmithKline, Lilly, and Bristol-Myers Squibb; and received research support from Abbott and GlaxoSmithKline. Dr. Kastelein has received consulting fees, lecture fees, and grant support from Pfizer, Merck Schering Plough, Bristol-Myers Squibb, and Sankyo, Munich, Germany; Dr. Kostis has served as a consultant to Pfizer, Schering Plough, Berlex, Montville, New Jersey; Taisho, Tokyo, Japan; Forest Laboratories, New York, New York; and Sankyo; received lecture fees from Pfizer, Merck, Bristol-Myers Squibb, AstraZeneca, Sanofi Aventis, and Otsuka, Rockville, Maryland; and received grant support from Pfizer and Schering Plough. Dr. Greten has received consulting and lecturing fees from Pfizer, Merck, Schering Plough, and Kowa Company, Nagoya, Japan.

Safety and Efficacy of Atorvastatin-Induced Very Low-Density Lipoprotein Cholesterol Levels in Patients With Coronary Heart Disease (a Post Hoc Analysis of the Treating to New Targets [TNT] Study)††Conflicts of interest: Dr. LaRosa has served as a consultant to Pfizer, Inc., New York, New York; Merck Whitehouse Station, New Jersey; Bristol-Myers Squibb, New York, New York; and AstraZeneca, Wilmington, Delaware; and has received lecture fees from Pfizer. Dr. Grundy has consulted with Abbott, Chicago, Illinois; GlaxoSmithKline, Durham, North Carolina, Pfizer, AstraZeneca, and Sanofi-Aventis, Bridgewater, New Jersey; received lecture fees from Merck Schering Plough, Kenilworth, New Jersey; Kos, Edison, New Jersey, Pfizer, GlaxoSmithKline, Lilly, and Bristol-Myers Squibb; and received research support from Abbott and GlaxoSmithKline. Dr. Kastelein has received consulting fees, lecture fees, and grant support from Pfizer, Merck Schering Plough, Bristol-Myers Squibb, and Sankyo, Munich, Germany; Dr. Kostis has served as a consultant to Pfizer, Schering Plough, Berlex, Montville, New Jersey; Taisho, Tokyo, Japan; Forest Laboratories, New York, New York; and Sankyo; received lecture fees from Pfizer, Merck, Bristol-Myers Squibb, AstraZeneca, Sanofi Aventis, and Otsuka, Rockville, Maryland; and received grant support from Pfizer and Schering Plough. Dr. Greten has received consulting and lecturing fees from Pfizer, Merck, Schering Plough, and Kowa Company, Nagoya, Japan.
デジタル記事
2007-09The American Journal of Cardiology100 5p.747-752
全国の図書館
  • 参照...atory analysis of the Standard Versu......tensive Statin Therapy for Patients with Hyperch...

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus11This study was sponsored by a grant from Fujisawa USA, Deerfield, Illinois.22The authors were working on behalf of the Tacrolimus US Heart Transplant Multicenter Study Group. Other members of the Study Group included (principal investigator listed first): UTAH Cardiac Transplant Program, Salt Lake City, Utah: David O. Taylor, MD, Dale G. Renlund, MD, Abdallah G. Kfoury, MD; St. Luke’s Episcopal Hospital/Texas Heart Institute, Houston, Texas: O. H. Frazier, MD, Branislav Radovancevic, MD, Edward K. Massin, MD; University of Wisconsin Hospitals and Clinics, Madison, Wisconsin: Robert M. Mentzer, Jr., MD, Charles C. Canver, MD, Robert B. Love, MD; Ochsner Medical Foundation, New Orleans, Louisiana: Frank W. Smart, MD, Hector O. Ventura, MD, Dwight D. Stapleton, MD, Mandeep Mehra, MD; University of Southern California, Los Angeles, California: Mark L. Barr, MD, Vaugh A. Starnes, MD; Medical College of Virginia, Richmond, Virginia: David E. Tolman, MD, Albert Guerraty, MD, David Salter, MD; Cleveland Clinic Foundation, Cleveland, Ohio: James B. Young, MD; Data Management and Statistical Coordinating Center-The EMMES Corporation, Potomac, Maryland: Paul VanVeldhuisen, MS, Anne Lindblad, PhD, Anita Yaffe, MSN, MPH.

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus11This study was sponsored by a grant from Fujisawa USA, Deerfield, Illinois.22The authors were working on behalf of the Tacrolimus US Heart Transplant Multicenter Study Group. Other members of the Study Group included (principal investigator listed first): UTAH Cardiac Transplant Program, Salt Lake City, Utah: David O. Taylor, MD, Dale G. Renlund, MD, Abdallah G. Kfoury, MD; St. Luke’s Episcopal Hospital/Texas Heart Institute, Houston, Texas: O. H. Frazier, MD, Branislav Radovancevic, MD, Edward K. Massin, MD; University of Wisconsin Hospitals and Clinics, Madison, Wisconsin: Robert M. Mentzer, Jr., MD, Charles C. Canver, MD, Robert B. Love, MD; Ochsner Medical Foundation, New Orleans, Louisiana: Frank W. Smart, MD, Hector O. Ventura, MD, Dwight D. Stapleton, MD, Mandeep Mehra, MD; University of Southern California, Los Angeles, California: Mark L. Barr, MD, Vaugh A. Starnes, MD; Medical College of Virginia, Richmond, Virginia: David E. Tolman, MD, Albert Guerraty, MD, David Salter, MD; Cleveland Clinic Foundation, Cleveland, Ohio: James B. Young, MD; Data Management and Statistical Coordinating Center-The EMMES Corporation, Potomac, Maryland: Paul VanVeldhuisen, MS, Anne Lindblad, PhD, Anita Yaffe, MSN, MPH.
デジタル記事
1999-04The Journal of Heart and Lung Transplantation18 4p.336-345
全国の図書館
  • 参照The efficacy of calcineurin inhibitors for the treatment of interstitial l......yositis Impact of tacrolimus ver......unction during the first year after heart transplant Sho......eatment Alters the Vascular Reactivity of Renal and Mesenteric Vascular...

The plays of Henry C. De Mille . The heart of Maryland & other plays

The plays of Henry C. De Mille . The heart of Maryland & other plays
紙図書
written in collaboration with David Belasco ; edited with an introductory essay by Robert Hamilton Ball . by David Belasco ; edited with an introduction and notes by Glenn Hughes and George SavageIndiana University Press1965, c1940
全国の図書館

Variations in Incidence of Diabetes among 10,000 Adult Israeli Males and the Factors Related to Their Development‖ ‖This report is based on work done in Israel as a collaborative project between the National Heart and Lung Institute, Bethesda, Maryland, the Hadassah Medical Organization, and the Ministry of Health, Jerusalem. It was supported by PL 480 counterpart funds, research agreement #375,106.

Variations in Incidence of Diabetes among 10,000 Adult Israeli Males and the Factors Related to Their Development‖ ‖This report is based on work done in Israel as a collaborative project between the National Heart and Lung Institute, Bethesda, Maryland, the Hadassah Medical Organization, and the Ministry of Health, Jerusalem. It was supported by PL 480 counterpart funds, research agreement #375,106.
デジタル記事
1978Advances in Metabolic Disordersp.93-110
全国の図書館
  • 参照Fat intake and the development of type 2 diabetes [Review]

The heart of Maryland & other plays

The heart of Maryland & other plays
紙図書
by David Belasco ; edited with an introduction and notes by Glenn Hughes and George SavagePrinceton University Press1941
全国の図書館

Pulmonary Vascular Changes in Tetralogy of Fallot* *From the Department of Pediatrics, State University of New York at Buffalo and the Edward J. Meyer Memorial Hospital. Presented at the 29th Annual Meeting, American College of Chest Physicians, Atlantic City, June 13-17, 1963.This work was aided by grants from the Heart Associations of Maryland and of Erie County, New York.

Pulmonary Vascular Changes in Tetralogy of Fallot* *From the Department of Pediatrics, State University of New York at Buffalo and the Edward J. Meyer Memorial Hospital. Presented at the 29th Annual Meeting, American College of Chest Physicians, Atlantic City, June 13-17, 1963.This work was aided by grants from the Heart Associations of Maryland and of Erie County, New York.
デジタル記事
1964-12Diseases of the Chest46 6p.664-670
全国の図書館
  • 参照Histologic Study of the Small Pulmonary Arteries in 3...